Gabelli Funds LLC Has $1.60 Million Holdings in Lantheus Holdings, Inc. $LNTH

Gabelli Funds LLC lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 55.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,000 shares of the medical equipment provider’s stock after selling 30,100 shares during the period. Gabelli Funds LLC’s holdings in Lantheus were worth $1,597,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in LNTH. Hantz Financial Services Inc. grew its position in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter worth approximately $36,000. Farther Finance Advisors LLC lifted its holdings in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $55,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Lantheus during the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Jefferies Financial Group reissued a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. Finally, Mizuho increased their price objective on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average target price of $99.71.

Lantheus Trading Up 9.0%

LNTH opened at $103.00 on Friday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $103.89. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average of $83.62 and a 200-day moving average of $71.76. The stock has a market cap of $6.71 billion, a PE ratio of 24.82 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the company posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.41 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.